Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.
Yosifov DY, Idler I, Bhattacharya N, Reichenzeller M, Close V, Ezerina D, Scheffold A, Jebaraj BMC, Kugler S, Bloehdorn J, Bahlo J, Robrecht S, Eichhorst B, Fischer K, Weigel A, Busch H, Lichter P, Döhner H, Dick TP, Stilgenbauer S, Mertens D. Yosifov DY, et al. Leukemia. 2020 Jan;34(1):115-127. doi: 10.1038/s41375-019-0513-x. Epub 2019 Jul 12. Leukemia. 2020. PMID: 31300746
From Biology to Therapy: The CLL Success Story.
Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. Yosifov DY, et al. Hemasphere. 2019 Feb 9;3(2):e175. doi: 10.1097/HS9.0000000000000175. eCollection 2019 Apr. Hemasphere. 2019. PMID: 31723816 Free PMC article. Review.
[No title available]
[No authors listed] [No authors listed] PMID: 31919090
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Tausch E, Beck P, Schlenk RF, Jebaraj BJ, Dolnik A, Yosifov DY, Hillmen P, Offner F, Janssens A, Babu GK, Grosicki S, Mayer J, Panagiotidis P, McKeown A, Gupta IV, Skorupa A, Pallaud C, Bullinger L, Mertens D, Döhner H, Stilgenbauer S. Tausch E, et al. Among authors: yosifov dy. Haematologica. 2020 Oct 1;105(10):2440-2447. doi: 10.3324/haematol.2019.229161. Haematologica. 2020. PMID: 33054084 Free PMC article. Clinical Trial.
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.
Tausch E, Ljungström V, Agathangelidis A, Zapatka M, Scarfò L, Jebaraj BMC, Yosifov DY, Müller A, Munugalavadla V, Degenhardt JD, Ghia P, Rosenquist R, Stilgenbauer S. Tausch E, et al. Among authors: yosifov dy. Blood. 2022 Jun 2;139(22):3340-3344. doi: 10.1182/blood.2021014550. Blood. 2022. PMID: 35377939 Free article. No abstract available.
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.
Qi J, Endres S, Yosifov DY, Tausch E, Dheenadayalan RP, Gao X, Müller A, Schneider C, Mertens D, Gierschik P, Wist M, Jebaraj BMC, Stilgenbauer S. Qi J, et al. Among authors: yosifov dy. Blood Adv. 2023 Oct 10;7(19):5698-5702. doi: 10.1182/bloodadvances.2022008955. Blood Adv. 2023. PMID: 36661329 Free PMC article. No abstract available.
19 results